Single-photon emission computed tomography

Global Nuclear Medicine Imaging Equipment Industry

Retrieved on: 
星期一, 二月 18, 2019
Medical physics, Neuroimaging, Medicine, Medicinal radiochemistry, Branches of biology, Radiobiology, Academic disciplines, Positron emission tomography, Radiation therapy, Single-photon emission computed tomography, Nuclear medicine

Table 104: Chinese 14-Year Perspective for Nuclear Medicine Imaging Equipment by Product Segment - Percentage Breakdown of Value Sales for SPECT Systems and PET Scanners Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

Key Points: 
  • Table 104: Chinese 14-Year Perspective for Nuclear Medicine Imaging Equipment by Product Segment - Percentage Breakdown of Value Sales for SPECT Systems and PET Scanners Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    Table 105: Indian Nuclear Medicine Market by Segment (2015): Percentage Breakdown of Volume Sales for Cyclotrons, Gamma Cameras and PET Scanners (includes corresponding Graph/Chart)
    Table 108: Indian 14-Year Perspective for Nuclear Medicine Imaging Equipment by Product Segment - Percentage Breakdown of Value Sales for SPECT Systems and PET Scanners Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    Table 109: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Medicine Imaging Equipment by Product Segment - SPECT Systems and PET Scanners Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    Table 111: Rest of Asia-Pacific 14-Year Perspective for Nuclear Medicine Imaging Equipment by Product Segment - Percentage Breakdown of Value Sales for SPECT Systems and PET Scanners Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    Table 112: Latin American Nuclear Medicine Procedures by Type (2015): Percentage Breakdown of Number of Procedures for Bone, Cardiovascular, Endocrine, Gastrointestinal, Lung and Others (includes corresponding Graph/Chart)
    Table 118: Latin American 14-Year Perspective for Nuclear Medicine Imaging Equipment by Geographic Region - Percentage Breakdown of Value Sales for Brazil and Rest of Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    Table 121: Latin American 14-Year Perspective for Nuclear Medicine Imaging Equipment by Product Segment - Percentage Breakdown of Value Sales for SPECT Systems and PET Scanners Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    Table 124: Brazilian 14-Year Perspective for Nuclear Medicine Imaging Equipment by Product Segment - Percentage Breakdown of Value Sales for SPECT Systems and PET Scanners Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    Table 125: Rest of Latin America Recent Past, Current & Future Analysis for Nuclear Medicine Imaging Equipment by Product Segment - SPECT Systems and PET Scanners Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    Table 127: Rest of Latin America 14-Year Perspective for Nuclear Medicine Imaging Equipment by Product Segment - Percentage Breakdown of Value Sales for SPECT Systems and PET Scanners Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    Table 128: Rest of World Recent Past, Current & Future Analysis for Nuclear Medicine Imaging Equipment by Product Segment - SPECT Systems and PET Scanners Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    Table 130: Rest of World 14-Year Perspective for Nuclear Medicine Imaging Equipment by Product Segment - Percentage Breakdown of Value Sales for SPECT Systems and PET Scanners Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    ReportLinker is an award-winning market research solution.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

New JACC Publication Reinforces Value of a Coronary CTA + HeartFlow Analysis-Guided Pathway for Diagnosing Heart Disease

Retrieved on: 
星期二, 一月 15, 2019
Technology, Software, Health, Cardiology, General Health, Medicine, Circulatory system, Cardiology, Fractional flow reserve, Angiography, Single-photon emission computed tomography, Draft:HeartFlow, Cardiac imaging

The HeartFlow Analysis is a non-invasive, personalized cardiac test that starts with a standard coronary computed tomography angiogram (CTA).

Key Points: 
  • The HeartFlow Analysis is a non-invasive, personalized cardiac test that starts with a standard coronary computed tomography angiogram (CTA).
  • The PACIFIC study included 208 patients who each underwent a coronary CTA, SPECT, PET and three-vessel invasive fractional flow reserve (FFR) measurements.
  • The HeartFlow Analyses were retrospectively obtained using data from the coronary CTA images.
  • HeartFlow, Inc. is a medical technology company redefining the way heart disease is diagnosed and treated.

New Study Shows Abbott's Novel Diagnostic Test has the Potential to Demonstrate Gold Standard Accuracy and Speed, Which Could Help Rule Out Heart Attacks Earlier at the Point of Care

Retrieved on: 
星期三, 十月 17, 2018
Medicine, Medical tests, Muscular system, Troponin, Point-of-care testing, Single-photon emission computed tomography

The goal of with-patient diagnostic tests is to deliver results with accuracy similar to the gold standard of high-sensitivity lab tests.

Key Points: 
  • The goal of with-patient diagnostic tests is to deliver results with accuracy similar to the gold standard of high-sensitivity lab tests.
  • "This is a major advancement in point-of-care test accuracy that may make possible significant improvements in patient care in both urban and rural settings."
  • The study found:
    Similar levels of accuracy between the two tests (area under the curve: 0.975 and 0.970 for the i-STAT TnI-Nx and hsTnI tests respectively).
  • The i-STAT cardiac troponin test from Abbott has been used in hospitals globally to help aid the physician in diagnosing heart attacks, right at the patient's bedside.

WMIS Presents 2018 Commercial Innovation of the Year Award to MILabs for VECTor-6 Broadband Photon Tomography

Retrieved on: 
星期一, 十月 15, 2018
Neuroimaging, Medical imaging, Medicine, Medical physics, Radiobiology, Sanilac County, Michigan, WMIC, Single-photon emission computed tomography, Tomography

MILabs was recognized for its latest innovation, VECTor-6 Broadband Photon Tomography, presented by Frederik Beekman, CEO/CSO, MILabs.

Key Points: 
  • MILabs was recognized for its latest innovation, VECTor-6 Broadband Photon Tomography, presented by Frederik Beekman, CEO/CSO, MILabs.
  • The WMIS community chooses the winner of the Commercial Innovation of the Year Award each year following presentations from 4-6 finalists at WMIC.
  • In addition to winning the 2018 award, MILabs was the recipient of the first-ever Commercial Innovation of the Year Award at WMIC 2015 in Hawaii for work in SPECT imaging.
  • The 5th annual Commercial Innovation of the Year Award will be given in Montral, Qubec, Canada at WMIC 2019.

Collaboration Between National Physical Laboratory and Mediso

Retrieved on: 
星期三, 十月 10, 2018
London boroughs, Medicine, Medical physics, London Borough of Richmond upon Thames, Neuroimaging, Medical imaging, Radiobiology, Medicinal radiochemistry, National Physical Laboratory, Nuclear medicine, Teddington, Single-photon emission computed tomography

Breakthrough scientific collaboration between National Physical Laboratory (NPL) and Mediso Medical Imaging Systems Ltd. has begun in the United Kingdom after installation of a newly procured triple modality AnyScan (SPECT/CT/PET) system.

Key Points: 
  • Breakthrough scientific collaboration between National Physical Laboratory (NPL) and Mediso Medical Imaging Systems Ltd. has begun in the United Kingdom after installation of a newly procured triple modality AnyScan (SPECT/CT/PET) system.
  • Andrew Robinson, Head of Nuclear Medicine Metrology, National Physical Laboratory, Teddington, Middlesex UK.
  • Mediso Ltd. works in the field of nuclear and molecular imaging focusing on development, manufacturing, sales and servicing of multi-modality in-vivo imaging systems.
  • The National Physical Laboratory (NPL) is the UK's National Measurement Institute, and is a world-leading centre of excellence in developing and applying the most accurate measurement standards, science and technology available.

Tulane National Primate Research Center Receives the 100th Mediso Preclinical PET System With Installation of the MultiScan Large FOV Extreme Resolution (LFER150) PET/CT

Retrieved on: 
星期二, 十月 2, 2018
Medicine, Medical physics, Neuroimaging, Nuclear medicine, Medical imaging, Radiobiology, Positron emission tomography–magnetic resonance imaging, Preclinical imaging, Positron emission tomography, Single-photon emission computed tomography, CT scan, Magnetic resonance imaging

The MultiScan LFER 150 PET/CT is the only research-focused, large bore integrated PET/CT scanner supporting whole-body imaging of non-human primates (NHPs) and smaller animal models at sub-millimeter PET resolution.

Key Points: 
  • The MultiScan LFER 150 PET/CT is the only research-focused, large bore integrated PET/CT scanner supporting whole-body imaging of non-human primates (NHPs) and smaller animal models at sub-millimeter PET resolution.
  • The LFER150 PET/CT will support TNPRC's research program in infectious diseases, particularly in tuberculosis research focused on vaccine development, pathogenesis, and therapeutics.
  • Like all preclinical PET/CT systems from Mediso, the LFER150 has been designed for quantitative assessment of PET and CT studies.
  • The nanoScan family is the first-line choice for preclinical imaging including the world's first integrated preclinical PET/MRI, PET/CT, SPECT/CT and SPECT/MRI combinations.

Huntsman Cancer Institute Becomes the First US Installation of the nanoScan 3 Tesla PET/MRI

Retrieved on: 
星期二, 十月 2, 2018
Medical physics, Medicine, Medical imaging, Nuclear medicine, Neuroimaging, Radiobiology, Positron emission tomography–magnetic resonance imaging, Preclinical imaging, Magnetic resonance imaging, Single-photon emission computed tomography, Preclinical SPECT

says Jeffrey Yap PhD, Co-Director, Center for Quantitative Cancer Imaging, Huntsman Cancer Institute.

Key Points: 
  • says Jeffrey Yap PhD, Co-Director, Center for Quantitative Cancer Imaging, Huntsman Cancer Institute.
  • "We are delighted to further expand the research capabilities of HCI enabling the use of quantitative multimodality imaging."
  • "The nanoScan PET/MRI 3T is the only integrated whole-body PET/MRI on the market that provides users with both high-end PET and 3T MRI.
  • Its nanoScan product family is the first-line choice for preclinical imaging including the world's first integrated preclinical PET/MRI, PET/CT, SPECT/CT and SPECT/MRI combinations.

Global Nuclear Medicine/Radiopharmaceutical Market Forecast to 2024: Drivers & Opportunities

Retrieved on: 
星期五, 七月 27, 2018
Medicine, Medicinal radiochemistry, Medical physics, Radiobiology, Nuclear medicine, Radiology, Market, Single-photon emission computed tomography, Compound annual growth rate, Economy, Health

The "Nuclear Medicine/Radiopharmaceutical Global Market - Forecast To 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nuclear Medicine/Radiopharmaceutical Global Market - Forecast To 2024" report has been added to ResearchAndMarkets.com's offering.
  • The nuclear medicine global market is estimated to reach $9,367.8 million by 2024 growing at mid single digit CAGR.
  • Diagnostics market held the largest market revenue in 2017 and is expected grow at single digit CAGR due to increase in SPECT and PET procedures.
  • The nuclear medicine global market is a competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring small companies for product expansion.

Global Nuclear Medicine/Radiopharmaceuticals Market, 2018-2024: Increase In Research Activities - Pharmaceuticals And Biotechnology Sectors

Retrieved on: 
星期三, 七月 18, 2018
Medicine, Health, Medical physics, Radiobiology, Clinical medicine, Radioactivity, Medicinal radiochemistry, Neuroimaging, Nuclear medicine, Radiation therapy, Brachytherapy, Single-photon emission computed tomography

Over the past 50 years nuclear medicine sector has displayed a strong link between investments in chemistry and development of radionuclide's and radiolabeled compounds.

Key Points: 
  • Over the past 50 years nuclear medicine sector has displayed a strong link between investments in chemistry and development of radionuclide's and radiolabeled compounds.
  • Non-invasive nuclear medicine imaging technique provides functional information at both molecular and cellular level and helps measuring the uptake and turnover of target-specific radiotracers in tissue.
  • The global nuclear medicine market by diagnosis is further divided into SPECT and PET while therapeutics market is segmented into alpha radiation therapy, beta radiation therapy and brachytherapy.
  • The major problem area of nuclear medicine market is closure of reactors.

Nuclear Medicine/Radiopharmaceuticals Global Market Estimated to be Worth $9,367.8 Million by 2024

Retrieved on: 
星期一, 七月 16, 2018
Medical physics, Medicine, Radiobiology, Nuclear medicine, Medicinal radiochemistry, Nuclear physics, Neuroimaging, Radiology, Technetium-99m, Single-photon emission computed tomography, Brachytherapy, Radiation therapy

As estimated by IQ4I Research, the nuclear medicine global market is expected to grow at high single digit CAGR to reach $9,367.8 million by 2024.

Key Points: 
  • As estimated by IQ4I Research, the nuclear medicine global market is expected to grow at high single digit CAGR to reach $9,367.8 million by 2024.
  • The nuclear medicine global market by modality is segmented into diagnostics (SPECT and PET) and therapeutics market (alpha radiation therapy, beta radiation therapy and brachytherapy).
  • As estimated by IQ4I Research, the stable isotope global market is expected to grow at high single digit CAGR to reach $256.9 million by 2024.
  • Analysis of the Nuclear Medicine global market share and individual product market shares like SPECT, PET and Tc-99m global market.